Table of Contents
Chapter 1. Global Breast Cancer Screening Tests Market Executive Summary
1.1. Global Breast Cancer Screening Tests Market Size & Forecast (2024-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Diagnostics Test Type
1.3.2. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Breast Cancer Screening Tests Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Breast Cancer Screening Tests Market Dynamics
3.1. Market Drivers
3.1.1. Rising Awareness and Early Detection Practices
3.1.2. Technological Advancements in Breast Cancer Screening
3.1.3. Increased Adoption of Genetic Testing
3.2. Market Challenges
3.2.1. False Positives and Overdiagnosis
3.2.2. High Cost of Advanced Screening Tests
3.3. Market Opportunities
3.3.1. Expansion of Breast Cancer Screening Initiatives
3.3.2. Technological Innovations in AI-Powered Diagnostics
Chapter 4. Global Breast Cancer Screening Tests Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Breast Cancer Screening Tests Market Size & Forecast by Diagnostics Test Type (2024-2032)
5.1. Segment Dashboard
5.2. Global Breast Cancer Screening Tests Market: Diagnostics Test Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Blood Marker Tests
5.2.2. Imaging Test
5.2.3. Genetic Test
5.2.4. Immunohistochemistry Test
Chapter 6. Global Breast Cancer Screening Tests Market Size & Forecast by End User (2024-2032)
6.1. Segment Dashboard
6.2. Global Breast Cancer Screening Tests Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Hospitals
6.2.2. Diagnostic Centres
6.2.3. Cancer Institutes
6.2.4. Research Laboratories
Chapter 7. Global Breast Cancer Screening Tests Market Size & Forecasts by Region (2024-2032)
7.1. North America Breast Cancer Screening Tests Market
7.1.1. U.S. Market
7.1.1.1. Diagnostics Test Type Breakdown Size & Forecasts (2024-2032)
7.1.2. Canada Market
7.1.2.1. Diagnostics Test Type Breakdown Size & Forecasts (2024-2032)
7.2. Europe Breast Cancer Screening Tests Market
7.2.1. U.K. Market
7.2.2. Germany Market
7.2.3. France Market
7.2.4. Spain Market
7.2.5. Italy Market
7.2.6. Rest of Europe Market
7.3. Asia-Pacific Breast Cancer Screening Tests Market
7.3.1. China Market
7.3.2. India Market
7.3.3. Japan Market
7.3.4. Australia Market
7.3.5. South Korea Market
7.3.6. Rest of Asia Pacific Market
7.4. Latin America Breast Cancer Screening Tests Market
7.4.1. Brazil Market
7.4.2. Mexico Market
7.4.3. Rest of Latin America Market
7.5. Middle East & Africa Breast Cancer Screening Tests Market
7.5.1. Saudi Arabia Market
7.5.2. South Africa Market
7.5.3. Rest of Middle East & Africa Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. General Electric Company
8.3.2. Myriad Genetics
8.3.3. Novartis
8.3.4. AstraZeneca
8.3.5. Biocrates Life Sciences AG
8.3.6. Pfizer
8.3.7. A&G Pharmaceutical, Inc.
8.3.8. Hologic Inc.
8.3.9. Siemens Healthineers
8.3.10. Koninklijke Philips NV
8.3.11. Fujifilm Holdings
8.3.12. Metabolomic Technologies, Inc.
8.3.13. Sanofi
8.3.14. Bayer AG
8.3.15. GlaxoSmithKline plc
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes